This company specializes in developing treatments for infectious diseases, with a portfolio of FDA-approved drugs, but currently has no active involvement in rare diseases or orphan drug designations.
0
Orphan Designations
20
FDA Approvals
Latest: TRIUMEQ PD (2022)
0
Active Trials
0
Rare Diseases
0
News (30d)
Quiet
ViiV Healthcare Company is a company with 0 orphan drug designations across 0 rare diseases, including 20 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
No pipeline data available yet.